Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin vs Empagliflozin in Egyptian T2DM Patients
NCT05359341Completed
- Sponsor
- Sadat City University
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sitagliptin and empagliflozin in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Sadat City University. Primary endpoint: Proportion of cured patients at 1 year. Started Sep 2020; status: completed.
02
Drugs
sitagliptinempagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05359341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05359341.